AgomAb Therapeutics NV - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AGMB Nasdaq 2830 www.agomab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AgomAb Therapeutics NV

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors - Aug 10th, 2026 2:07 pm
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook - Aug 6th, 2026 2:01 pm
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential? - Jul 2nd, 2026 2:06 pm
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease - Jun 23rd, 2026 3:32 pm
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease - Jun 23rd, 2026 2:05 pm
Agomab to Participate in Upcoming Conferences - May 14th, 2026 5:30 am
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - Apr 23rd, 2026 4:14 pm
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447 - Apr 12th, 2026 12:46 pm
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - Mar 26th, 2026 5:00 am
European Equities Traded in the US as American Depositary Receipts Higher Wednesday - Feb 18th, 2026 9:15 am
Agomab Announces Closing of Initial Public Offering - Feb 9th, 2026 2:05 pm
Agomab indicated to open at $15.50, IPO priced at $16 - Feb 7th, 2026 8:55 am
Agomab Announces Pricing of Initial Public Offering - Feb 5th, 2026 5:24 pm